Abbott’s Drug Eluting Coronary Stent brings clinical pedigree to Canada
Abbott has seen its XIENCE Xpedition™ Everolimus Eluting Coronary Stent System received Health Canada approval. The company is launching it immediately in the country, providing physicians with a next-generation technology with the largest size matrix currently available in the Canadian market. Abbott claims the XIENCE Xpedition family features a new stent delivery system designed to optimize deliverability, particularly in challenging coronary anatomies.
Abbott’s XIENCE Xpedition is supported by the robust clinical evidence of the XIENCE family of stents, including data from more than 53,000 patients across more than 100 studies with long-term outcomes. Data have consistently shown an excellent safety and efficacy profile for the XIENCE family of stents.
What the physicians say
Dr. André Kokis, M.D., interventional cardiologist at Centre Hospitalier de l’Université de Montréal (CHUM), was the first physician to treat a patient with XIENCE Xpedition in Canada.
“The combination of excellent deliverability, wide availability of sizes, and compelling clinical evidence from the XIENCE family of stents make XIENCE Xpedition well suited to treat a wide range of patients with simple and complex coronary disease,” said Dr. Kokis. “The technical advancements in the stent delivery system enable physicians to navigate complex coronary anatomy with confidence, making XIENCE Xpedition an important advancement in drug eluting stent technology.”